Preparation and characterization of Δ⁹-tetrahydrocannabinol-loaded biodegradable polymeric microparticles and their antitumoral efficacy on cancer cell lines

References

• Mechoulam R, Peters M, Murillo-Rodriguez E, et al. Cannabidiol – recent advances. Chem Biodivers 2007;4:1678–92
   PubMed Web of Science ®Google Scholar
• Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. Br J Pharmacol 2008;153:199–215
   PubMed Web of Science ®Google Scholar
• Izzo AA, Borrelli F, Capasso R, et al. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 2009;30:515–27
   PubMed Web of Science ®Google Scholar
• Pertwee RG. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 2009;156:397–411
   PubMed Web of Science ®Google Scholar
• Guzmán M. Cannabinoids: potential anticancer agents. Nat Rev Cancer 2003;3:745–55
   PubMed Web of Science ®Google Scholar
• Ben Amar M. Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol 2006;105:1–25
   PubMed Web of Science ®Google Scholar
• Hanuš LO. Pharmacological and therapeutic secrets of plant and brain (endo)cannabinoids. Med Res Rev 2009;29:213--71
   Google Scholar
• Parolaro D, Massi P. Cannabinoids as potential new therapy for the treatment of gliomas. Expert Rev Neurother 2008;8:37–49
   PubMedGoogle Scholar
• Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 2003;42:327–60
   PubMed Web of Science ®Google Scholar
• Ohlsson A, Lindgren JE, Andersson S, et al. Single-dose kinetics of deuterium-labelled cannabidiol in man after intravenous administration and smoking. Biomed Environ Mass Spectrom 1986;149:495–9
   Google Scholar
• Mannila J, Järvinen T, Järvinen K, et al. Precipitation complexation method produces cannabidiol/beta-cyclodextrin inclusion complex suitable for sublingual administration of cannabidiol. J Pharm Sci 2007;96:312–19
   PubMed Web of Science ®Google Scholar
• Doyle E, Spence AA. Cannabis as a medicine? Br J Anaesth 1995;74:359–61
   PubMed Web of Science ®Google Scholar
• Mattes RDShaw LM, Edling-Owens J, et al. Bypassing the first-pass effect for the therapeutic use of cannabinoids. Pharmacol Biochem Behav 1993;44:745–7
   PubMed Web of Science ®Google Scholar
• Hazekamp A, Verpoorte R. Structure elucidation of the tetrahydrocannabinol complex with randomly methylated [beta]-cyclodextrin. Eur J Pharm Sci 2006;29:340–7
   PubMed Web of Science ®Google Scholar
• Ohlsson A, Lindgren JE, Wahlen A, et al. Plasma delta-9-tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther 1980;28:409–16
   PubMed Web of Science ®Google Scholar
• Garrett ER, Tsau J. Stability of tetrahydrocannabinols I. J Pharm Sci 1974;63:1563–74
   PubMed Web of Science ®Google Scholar
• Grotenhermen F. Cannabinoids for therapeutic use. Designing systems to increase efficacy and reliability. Am J Drug Deliv 2004;24:229–40
   Google Scholar
• Thomas BF, Compton DR, Martin BR. Characterization of the lipophilicity of natural and synthetic analogs of delta 9-tetrahydrocannabinol and its relationship to pharmacological potency. J Pharmacol Exp Ther 1990;255:624–30
   PubMed Web of Science ®Google Scholar
• van Drooge D-J, Hinrichs WLJ, Dickhoff BHJ, et al. Spray freeze drying to produce a stable Δ9-tetrahydrocannabinol containing inulin-based solid dispersion powder suitable for inhalation. Eur J Pharm Sci 2005;26:231–40
   PubMed Web of Science ®Google Scholar
• Mechoulam R. Marihuana chemistry. Science 1970;168:1159–66
   PubMed Web of Science ®Google Scholar
• Munjal M, ElSohly MA, Repka MA. Chemical stabilization of a Delta9-Tetrahydrocannabinol prodrug in polymeric matrix systems produced by a hot-melt method: role of microenvironment pH. AAPS PharmSciTech 2006;7:E1--E12
   PubMedGoogle Scholar
• Garrett ER, Hunt A. Physicochemical properties, solubility, and protein binding of D9-tetrahydrocannabinol. J Pharm Sci 1974;63:1056–64
   PubMed Web of Science ®Google Scholar
• Jarho P, Pate DW, Brenneisen R, et al. Hydroxypropyl-beta-cyclodextrin and its combination with hydroxypropyl-methylcellulose increases aqueous solubility of delta9-tetrahydrocannabinol. Life Sci 1998;63:PL381–4
   PubMed Web of Science ®Google Scholar
• Wilson DM, Peart J, Martin BR, et al. Physiochemical and pharmacological characterization of a Δ9-THC aerosol generated by a metered dose inhaler. Drug Alcohol Depend 2002;67:259–67
   PubMed Web of Science ®Google Scholar
• Hernán Pérez de la Ossa D, Ligresti A, Gil-Alegre ME, et al. Poly-ε-caprolactone microspheres as a drug delivery system for cannabinoid administration: development, characterization and in vitro evaluation of their antitumoral efficacy. J Controlled Release 2012;161:927–32
   PubMed Web of Science ®Google Scholar
• Alexander A, Smith PF, et al. Cannabinoids in the treatment of cancer. Cancer Lett 2009;285:6–12
   PubMed Web of Science ®Google Scholar
• Guzmán M, et al. Effects on cell viability. Handb Exp Pharmacol 2005;168:627–42
   PubMedGoogle Scholar
• Patsos HAHicks DJ, Greenhough A. Cannabinoids and cancer: potential for colorectal cancer therapy. Biochem Soc Trans 2005;33:712–14
   PubMed Web of Science ®Google Scholar
• Ligresti A, Bisogno T, et al. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 2003;125:677–87
   PubMed Web of Science ®Google Scholar
• Caffarel MM, Moreno-Bueno G, Cerutti C, et al. JunD is involved in the antiproliferative effect of [Delta]9-tetrahydrocannabinol on human breast cancer cells. Oncogene 2008;27:5033–44
   PubMed Web of Science ®Google Scholar
• Walsh D, Nelson K, Mahmoud F, et al. Established and potential therapeutic applications of cannabinoids in oncology. Support Care Cancer 2003;11:137–43
   PubMed Web of Science ®Google Scholar
• Mechoulam R. Chemistry of cannabis. Handbook Exp Pharmacol 1981;55:119–34
   Google Scholar
• Gill EW, Jones G. Brain levels of Δ1-THC and its metabolites in mice. Biochem Pharmacol 1972;21:2237–48
   PubMed Web of Science ®Google Scholar
• Shi Y, Li LC. Current advances in sustained-release systems for parenteral drug delivery. Expert Opin Drug Deliv 2005;2:1039–58
   PubMedGoogle Scholar
• Sinha VR, Bansal K, et al. Poly-[epsilon]-caprolactone microspheres and nanospheres: an overview. Int J Pharm 2004;278:1–23
   PubMed Web of Science ®Google Scholar
• Li Z, Li Q, Simon S, et al. Formulation of spray-dried phenytoin loaded poly(ε-caprolactone) microcarrier intended for brain delivery to treat epilepsy. J Pharm Sci 2007;96:1018–30
   PubMed Web of Science ®Google Scholar
• Ligresti A, Moriello AS, Starowicz K, et al. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther 2006;318:1375–87
   PubMed Web of Science ®Google Scholar
• Repka MA, Munjal M, ElSohly MA, et al. Temperature stability and bioadhesive properties of delta-9-tetrahydrocannabinol incorporated hydroxypropylcellulose polymer matrix systems. Drug Dev Ind Pharm 2006;32:21–32
   PubMed Web of Science ®Google Scholar
• Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci 2001;13:123–33
   PubMed Web of Science ®Google Scholar
• Barcia E, Herradón C, Herrero-Vanrell R. Biodegradable additives modulate ganciclovir release rate from PLGA microspheres destined to intraocular administration. Lett Drug Design Discov 2005;2:148–9
   Web of Science ®Google Scholar
• Martínez-Sancho C, Herrero-Vanrell R, Negro S. Poly(D,L-lactide-co-glycolide) microspheres for long-term intravitreal delivery of aciclovir: influence of fatty and non-fatty additives. J Microencapsul 2003;20:799–810
   PubMed Web of Science ®Google Scholar
• Mu L, Feng SS. A novel controlled release formulation for the anticancer drug paclitaxel (Taxol®): PLGA nanoparticles containing vitamin E TPGS. J Controlled Release 2003;86:33–48
   PubMed Web of Science ®Google Scholar
• Forrest ML, Won C-Y, Malick AW, et al. In vitro release of the mTOR inhibitor rapamycin from poly(ethylene glycol)-b-poly(ε-caprolactone) micelles. J Controlled Release 2006;110:370–7
   PubMed Web of Science ®Google Scholar
• Menei P, Boisdron-Celle M, Croué A, et al. Effect of stereotactic implantation of biodegradable 5-fluorouracil-loaded microspheres in healthy and C6 glioma-bearing rats. Neurosurgery 1996;39:117–23
   PubMed Web of Science ®Google Scholar